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Background: Renal ischemia reperfusion (IR) injury has been a major source of concern during the past 
decades and angiotensin converting enzyme (ACE) inhibitors have been successfully used to prevent this 
injury. There have been some controversial reports about the involvement of KATP channels in the mechanism 
of action of ACE inhibitors. In this study, we examined the effect of KATP channel blocker (Glibenclamide) on 
preventive effect of captopril on renal IR injury. Methods: Male sprauge-dawley rats were pretreated with 
glibenclamide (1, 5 and 25 mg/kg) and/or captopril (5 mg/kg). They were anesthetized using ketamine (50 
mg/kg) and xylazine (10 mg/kg). The left flank was incised and the left renal artery was clamped for 30 
minutes. After that, the kidney was reperfused for 2 hours and then the animal was killed. The Right and left 
kidneys were removed and evaluated for microscopic damage. Results: Captopril reduced renal IR injury 
while glibenclamide by itself caused no change. Glibenclamide did not change the preventive effect of 
captopril. Conclusion: It seems that the preventive effect of captopril is not directly mediated by KATP 
channels and further attention should be paid to other receptor-mediated angiotensin II effects.  Iran. Biomed. J. 
12 (4): 241-245, 2008 
 





eperfusion is known to produce ischemic and 
hypoxic lesions in vivo and in vitro in 
different organs [1]. Several factors have 
been implicated in the pathophysiological changes 
of ischemia reperfusion (IR) injury [2].   There has 
been great interest in the role of renin angiotensin 
system and in particular angiotensin II (Ang II) in 
cardiovascular and renal physiology and pathology. 
Until the last decade, this interest was directed only 
towards the haemodynamic effect of angiotensin as a 
vasopeptide [3]. The discovery of angiotensin 
converting enzyme (ACE) inhibitors added a new 
dimension to our understanding of non-
homodynamic effects of Ang II [4-6]. Captopril, a 
ACE inhibitor, has been successfully used in 
protecting against IR induced renal injury. 
 In general, Ang II stimulation facilitates the 
protein kinase C (PKC) activation. The involvement 
of PKC pathway for the regulation of KATP, however, 
remained controversial [7-11]. KATP Channels [12] 
activate and serve as metaboelectrical sensors, 
thereby regulate the duration of action potential, Ca2+ 
influx, and myocardial contractility [13]. The 
activation of the channels minimizes the infarct size 
in several animal models [14]. KATP channel 
regulation of vasoactivity in vascular beds, including 
the renal medulla, has been examined by testing the 
ability of glibenclamide to lower blood flow. 
Gardiner and colleagues [15] found that 
glibenclamide infusion into rats induced renal 
vasoconstriction. In the kidney, a role for 
modulation of arteriolar tone by KATP channels has 
R 
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been repeatedly observed [16, 17]. There have been 
some controversial reports about the involvement of 
KATP channels in the mechanism of action of ACE 
inhibitors. Some believe that ACE inhibitors’ 
mechanism of action is mediated by KATP channels 
[18] while others disagree with this concept [19]. In 
this study, we examined the effect of captopril on 
renal IR injury in the presence and absence of 
glibenclamide (KATP channel blocker). 
 
 
MATERIALS AND METHODS 
 
 Animals. Male sprauge-dawley rats weighting 150 
to 200 grams with free access to food and water, 
were divided into 9 groups each containing 7 rats 
(Table 1). Animals were pretreated with 
intraperitoneal glibenclamide (1, 5 and 25 mg/kg) 2 
hours before surgical procedure  and/or  
subcutaneous captopril (5 mg/kg) one hour before 
surgical procedure. We measured blood pressure in 
all groups before ischemia. 
 
 Surgical procedure. The surgical procedure was 
based on two kidneys one clamped (2K1C) model. 
Animals were anesthetized using xylazine (10 mg/kg) 
and ketamine hydrochloride (50 mg/kg) 
intraperitonealy. In sham operation group, the left 
flank was incised and then closed without any 
further manipulation. In other groups, the left flank 
was incised and the left renal artery was exposed. 
Then, it was clamped using an arterial clamp 
(Ischemic phase). The skin was temporarily closed 
and animal was kept in a suitable warm environment. 
After 30 minutes of ischemia, the arterial clamp was 
removed and the skin was closed (Reperfusion 
phase). Two hours later, animal was killed and both 
kidneys were removed and fixed in 10% formalin. 
 
 Study groups. Animals were randomly assigned to 
one of the following groups of 7 rats each. Group I 
was the control group (sham operated). Group II 
received normal saline by the subcutaneous route 2 
hours before the occlusion of renal artery. Group III 
received 5 mg/kg captopril, groups IV, V and VI 
received glibenclamide 1, 5 and  25 mg/kg, 
respectively before IR and groups VII, VIII and IX 
received glibenclamide 1, 5 and 25 mg/kg, 
respectively before pretreatment with captopril 5 
mg/kg and then IR was induced.  
 
 Pathological evaluation. The samples were 
stained using H and E technique and evaluated for 
microscopic damage. The left kidney was compared 
to the right kidney (control) and reperfusion injury 
was graded based on its severity as follow: 0, No 
damage seen; 1, Necrosis of individual cells; 2, 
Necrosis of all adjacent proximal convoluted tubules, 
with survival of surrounding tubules; 3, Necrosis 
confined to the distal third of the proximal 
convoluted tubules with a band of necrosis 
extending into the inner cortex; 4, Necrosis affecting 
all the three segments of the proximal convoluted 
tubules [20]. 
 
 Drugs. Captopril was purchased from Quimica 
Sintetica, S.A., Spain. Glibenclamide was purchased 
from Tehran-Darou Pharm. Co., Iran. Xylazine and 





   Table1. Grading the effects of different doses of captopril and glibenclamide on ischemia reperfusion-
induced renal injury in rats. 
Group Treatment Grading the Histological severity
 
0 1 2 3 4 
I Saline + SO 7 0 0 0 0 
II Saline + IRS 0 0 0 7 0 
III Capto 5 mg/kg + IRS 0 5 2 0 0 
IV Gli 1mg/kg + IRNS 0 0 1 6 0 
V Gli 5mg/kg + IRNS 0 0 1 6 0 
VI Gli 25mg/kg + IRNS 0 0 0 6 1 
VII Gli 1mg/kg + Capto 5mg/kg + IRNS 0 6 1 0 0 
VIII Gli 5mg/kg + Capto 5mg/kg + IRNS 0 5 2 0 0 
IX Gli 25mg/kg + Capto 5mg/kg + IRNS 0 6 1 0 0 
SO, sham operation; IR, ischemia  reperfusion; Capto, captopril; Gli, glibenclamide; S, significant difference; 
NS, non-significant difference. Group II was compared to group I.  Groups III, IV, V, VI were compared to 
group II. Groups VII, VIII, IX were compared to group III. 
Iran. Biomed. J., October 2008                                 Interaction of Captopril and KATP                                                                         243                       
 
http://IBJ.pasteur.ac.ir 
 Statistical evaluation. Mann-Whitney mean rank 
test was used to assess the significance of 
differences between treated groups. Differences 
among groups were considered significant at P value 
of ≤ 0.05. Calculations were performed using the 





   Subcutaneous injection of saline and subsequent 
sham operation caused no renal injury. Saline and 
subsequent ischemia and reperfusion caused renal 
injury with pathologic grades of 3 and 4. Captopril 
(5 mg/kg) reduced the IR injury to grade 1 and this 
reduction was statistically significant (P<0.05) 
compared to IR group. Glibenclamide itself (1, 5 and 
25 mg/kg) could not change the grading of renal 
injury, while pretreatment with glibenclamide (1, 5 
and 25 mg/kg) caused no change in protective effect 
of captopril (Table 1). Indeed, we have not seen any 





 In this study, we found out that IR caused severe 
renal injury and captopril was able to prevent this 
damage. Ang II is a potent vasoconstrictor, known to 
activate channels that depolarize vascular smooth 
muscle and allow Ca2+entry. Its effects in reducing 
the activity of K+ channels should enhance its action 
in causing membrane depolarization, and so 
contribute to its vasoconstrictor action, since 
voltage-activated Ca2+ channels, and so Ca2+ entry 
are highly sensitive to small changes in membrane 
potential. Further, it is clear that the activity of such 
channels contributes to resting blood flow in a 
number of vascular beds including those of the 
coronary, mesenteric, skeletal muscle and renal 
circulations, since glibenclamide increases resistance 
to blood flow in those tissues. Since KATP channel 
activity is increased by a number of vasodilators and 
by metabolic stress such as hypoxia, the potential for 
inhibition by Ang II to reduce K+ conductance 
should also be increased under such conditions. 
Thus, the action of Ang II in inhibiting KATP 
channels via activation of PKC described here may 
make an important contribution to the 
vasoconstrictor action of the peptide [18, 21]. 
 Antagonization of Ang II action by ACE inhibitors 
improves the symptoms of congestive heart failure 
and reduces reperfusion injury and arrhythmias [22-
24]. Using the rat model, Linz et al demonstrated 
that ACE inhibitors reduce both ischemic areas at 
risk and zones of infarcted muscle. The inhibitory 
pathway of KATP may be one of several actions of 
Ang II and in part account for the cardioprotective 
and renoprotective actions of ACE inhibitors [25-27].  
 There have been some controversial reports that 
ACE inhibitors’ mechanism of action is/isn’t 
mediated by KATP channels [18, 19]. The results of 
this study showed that the protective effect of 
captopril (ACE inhibitor) is not affected by 
glibenclamide (KATP channel blocker). One might 
propose that the protective effect of captopril is not 
mediated by KATP channels but some data suggest 
that there might be some sort of relationship 
between these two. Sargent et al have indicated that 
SH containing ACE inhibitors (captopril like) show 
an effect on KATP channel open probability in 
vascular smooth muscle but Koppel et al. [19] 
showed that there is little or no effect on KATP 
channels due to the presence of SH branch. This 
protective effect of captopril did not change in the 
presence of glibenclamide (inhibitor KATP 
channel). From our experiments, we conclude that 
the postulated opening of KATP channels by SH-
group-containing ACE inhibitors contributes to the 
vasodilation of vascular/microvascular kidney 
caused by ACE inhibitors, and that SH groups have 
no influence upon KATP channels of  
vascular/microvascular kidney. Also, our recent 
study showed that ACE inhibitor was able to 
attenuate kidney IR injury and this preventive effect 
may be independent of Ang II AT1 receptors [28]. It 
seems logical to expect some kind of relationship 
between ACE inhibitors and KATP channels. Our 
study indicates that no direct relationship exists 
between these two but further exploration focused 
on other mechanisms of Ang II receptor-mediated 
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